Trial · NCT07279584
Golidocitinib Combined With GemOx in RR PTCL
NCT07279584, Phase 2, Not yet recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Golidocitinib Combined With GemOx in RR PTCL. Trials, record NCT07279584. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07279584
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Golidocitinib Combined With GemOx in RR PTCL
- NCT number
- NCT07279584
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 31 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Peripheral T-cell Lymphomas (PTCL)
- Interventions
- golidocitinib, GEMOX
- First posted
- 2025-12-12
- Last updated
- 2025-12-12
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate | Tumor evaluation was assessed at screening and at the end of treatment (around 3 cycles) then every 12-24 weeks until disease progression (each cycle is 21 days) through study completion, an average of 1 year. | Percentage of participants with complete response partial response was determined on the basis of investigator assessments according to 2014 Lugano criteria. |
| Secondary | Progression-free survival | Baseline up to data cut-off(up to approximately 2 years) | Progression-free survival was defined as the time from the date of randomization until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first. |
| Secondary | Complete Response Rate | Tumor evaluation was assessed at screening and at the end of treatment (around 3 cycles) then every 12-24 weeks until disease progression (each cycle is 21 days) through study completion, an average of 1 year. | Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria. |
| Secondary | Duration of Response | Baseline up to data cut-off(up to approximately 2 years) | Applicable to complete or partial response participants. DoR was defined as the time from the first documented date of complete or partial response until the date of the disease progression or death from any causes. |
| Secondary | Overall survival | Baseline up to data cut-off(up to approximately 2 years) | Percentage of participants with complete or partial response was determined on the basis of investigator assessments according to 2014 Lugano criteria. |
| Secondary | Adverse Events | Baseline up to data cut-off(up to approximately 3 years) | Adverse Events are assessed based on CTCAE v5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07279584
GET https://conductscience.org/api/trials/v1/NCT07279584/registered